TD Cowen analyst Yaron Werber has maintained their bullish stance on IONS stock, giving a Buy rating on December 1.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yaron Werber has given his Buy rating due to a combination of factors that highlight Ionis Pharmaceuticals’ promising growth trajectory. A significant driver of this optimism is the anticipated robust sales growth in 2026, fueled by the launch of several key products such as Tryngolza for severe hypertriglyceridemia and Dawnzera for hereditary angioedema. Additionally, Ionis is expected to benefit from incremental growth in Spinraza sales, a leading therapy for spinal muscular atrophy, through its collaboration with Biogen.
Ionis Pharmaceuticals is also positioned for long-term success due to its industry-leading portfolio of antisense oligonucleotides targeting a range of diseases. The company’s strategic partnerships with major pharmaceutical firms like Biogen and AstraZeneca, along with potential collaborations with Novartis, GSK, and Roche, further bolster its growth prospects. Moreover, the upcoming clinical data and regulatory milestones for several pipeline products present additional opportunities for both near- and long-term upside, reinforcing the Buy rating.
According to TipRanks, Werber is a 5-star analyst with an average return of 21.4% and a 60.16% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, BioNTech SE, and Roivant Sciences.